Genmab A/S (NASDAQ:GMAB) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $45.20.

GMAB has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. BMO Capital Markets reaffirmed an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Redburn Atlantic started coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. Truist Financial dropped their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th.

Genmab A/S Trading Up 0.9 %

Shares of GMAB stock opened at $20.65 on Monday. Genmab A/S has a 12 month low of $20.34 and a 12 month high of $32.88. The stock has a market cap of $13.67 billion, a P/E ratio of 20.05, a P/E/G ratio of 0.64 and a beta of 0.99. The company has a 50 day simple moving average of $23.16 and a two-hundred day simple moving average of $25.86.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). The company had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the company earned $0.47 earnings per share. As a group, equities analysts forecast that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its stake in shares of Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after buying an additional 544 shares during the period. Allspring Global Investments Holdings LLC increased its position in Genmab A/S by 123.0% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock valued at $81,000 after purchasing an additional 1,787 shares during the period. Blue Trust Inc. raised its holdings in shares of Genmab A/S by 892.0% in the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares in the last quarter. Headlands Technologies LLC lifted its position in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.